Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$12.34
+0.8%
$14.75
$7.17
$18.23
$426.27M0.87426,154 shs837,215 shs
National Vision Holdings, Inc. stock logo
EYE
National Vision
$24.73
+6.0%
$20.15
$9.56
$25.06
$1.84B1.271.91 million shs3.61 million shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$83.91
+1.1%
$82.83
$71.42
$109.58
$1.87B0.82169,402 shs128,206 shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.51
+3.7%
$17.65
$14.17
$34.13
$1.88B0.721.13 million shs1.36 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
+0.82%-3.29%-24.66%+8.15%+56.01%
National Vision Holdings, Inc. stock logo
EYE
National Vision
+6.00%+2.19%+17.59%+107.82%+93.35%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+1.12%+0.26%-0.26%+0.01%+1.27%
NovoCure Limited stock logo
NVCR
NovoCure
+3.67%-2.07%+3.00%+3.30%+9.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.2342 of 5 stars
3.55.00.00.01.12.50.6
National Vision Holdings, Inc. stock logo
EYE
National Vision
2.6255 of 5 stars
2.32.00.03.32.10.80.0
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
1.901 of 5 stars
2.21.03.30.00.02.51.3
NovoCure Limited stock logo
NVCR
NovoCure
3.5856 of 5 stars
3.41.00.04.51.91.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$24.0094.49% Upside
National Vision Holdings, Inc. stock logo
EYE
National Vision
2.56
Moderate Buy$22.10-10.63% Downside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.33
Hold$97.8316.59% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.71
Moderate Buy$32.4385.20% Upside

Current Analyst Ratings Breakdown

Latest DCTH, NVCR, LMAT, and EYE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
7/8/2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
National Bankshares
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$30.00
7/8/2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$17.00 ➝ $30.00
7/8/2025
NovoCure Limited stock logo
NVCR
NovoCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/23/2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00
6/18/2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $26.00
5/23/2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $29.00
5/19/2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetMarket Perform ➝ Market Perform$13.00 ➝ $19.00
5/12/2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $17.00
5/9/2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$13.00 ➝ $17.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$37.21M11.55N/AN/A$2.15 per share5.74
National Vision Holdings, Inc. stock logo
EYE
National Vision
$1.82B1.07$1.73 per share14.26$10.37 per share2.38
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$219.86M8.62$2.42 per share34.74$15.00 per share5.59
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.23N/AN/A$3.33 per share5.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/4/2025 (Estimated)
National Vision Holdings, Inc. stock logo
EYE
National Vision
-$28.50M-$0.33N/A91.593.42-1.40%3.44%1.40%8/6/2025 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$44.04M$1.9842.3838.672.1919.96%13.53%9.78%7/30/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)

Latest DCTH, NVCR, LMAT, and EYE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
$0.12N/AN/AN/A$469.21 millionN/A
8/4/2025Q2 2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$0.02N/AN/AN/A$22.84 millionN/A
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/8/2025Q1 2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$0.10$0.03-$0.07$0.03$16.83 million$19.80 million
5/7/2025Q1 2025
National Vision Holdings, Inc. stock logo
EYE
National Vision
$0.32$0.34+$0.02$0.18$510.30 million$510.32 million
5/1/2025Q1 2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.50$0.48-$0.02$0.48$57.61 million$59.87 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
National Vision Holdings, Inc. stock logo
EYE
National Vision
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.800.95%N/A40.40%14 Years
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A

Latest DCTH, NVCR, LMAT, and EYE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.201%5/15/20255/15/20255/29/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
15.95
14.61
National Vision Holdings, Inc. stock logo
EYE
National Vision
0.29
0.54
0.35
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
0.48
16.49
13.83
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41

Institutional Ownership

CompanyInstitutional Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
National Vision Holdings, Inc. stock logo
EYE
National Vision
N/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
17.94%
National Vision Holdings, Inc. stock logo
EYE
National Vision
2.70%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
9.50%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
6034.83 million28.58 millionOptionable
National Vision Holdings, Inc. stock logo
EYE
National Vision
13,41179.05 million76.92 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
49022.59 million20.45 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable

Recent News About These Companies

Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.83
What Makes NovoCure (NVCR) a New Buy Stock
NovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Delcath Systems stock logo

Delcath Systems NASDAQ:DCTH

$12.34 +0.10 (+0.82%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$12.57 +0.23 (+1.86%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

National Vision stock logo

National Vision NASDAQ:EYE

$24.73 +1.40 (+6.00%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$25.06 +0.33 (+1.33%)
As of 08:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

LeMaitre Vascular stock logo

LeMaitre Vascular NASDAQ:LMAT

$83.91 +0.93 (+1.12%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$83.90 -0.02 (-0.02%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.51 +0.62 (+3.67%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$17.63 +0.12 (+0.66%)
As of 07:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.